866-997-4948(US-Canada Toll Free)

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 48 Pages

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2017

Summary

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Metabotropic glutamate receptor 3 is a G protein-coupled receptor encoded by the GRM3 gene. L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory autoreceptor and heteroceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Oncology which include indications Depression, Parkinson's Disease, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Chronic Pain, Cognitive Impairment, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Glioma, Schizophrenia and Treatment Resistant Depression.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)
- The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Overview 6
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development 18
Addex Therapeutics Ltd 18
Aevi Genomic Medicine Inc 18
Denovo Biopharma LLC 19
Domain Therapeutics SA 19
Eli Lilly and Company 20
Prexton Therapeutics SA 20
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles 21
DT-010991 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
DT-011088 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
fasoracetam - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
LY-2969822 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
LY-3020371 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
LY-341495 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
pomaglumetad methionil - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecules to Agonize mGluR3 for Parkinson's Disease - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecules to Modulate mGlu3 Receptor for CNS Disorders - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
VU-0092273 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
VU-0650786 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Products 35
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products 37
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Product Development Milestones 38
Featured News & Press Releases 38
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 38
Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 38
Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 40
Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 40
Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome 41
Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents 42
Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder 42
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD 43
Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinsons disease with renewed support by The Michael J. Fox Foundation 44
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results 44
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study 45
Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research 45
Sep 02, 2007: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 16
Number of Products by Stage and Molecule Type, H2 2017 17
Pipeline by Addex Therapeutics Ltd, H2 2017 18
Pipeline by Aevi Genomic Medicine Inc, H2 2017 18
Pipeline by Denovo Biopharma LLC, H2 2017 19
Pipeline by Domain Therapeutics SA, H2 2017 19
Pipeline by Eli Lilly and Company, H2 2017 20
Pipeline by Prexton Therapeutics SA, H2 2017 20
Dormant Products, H2 2017 35
Dormant Products, H2 2017 (Contd..1), H2 2017 36
Discontinued Products, H2 2017 37

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Stage and Route of Administrations, H2 2017 16
Number of Products by Stage and Molecule Types, H2 2017 17

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *